Tarsus Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.84.
During the past 3 years, the average EBIT per Share Growth Rate was 12.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -3.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Tarsus Pharmaceuticals's EBIT per Share or its related term are showing as below:
TARS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -75.7 Med: -11.9 Max: 12.6
Current: 12.6
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Tarsus Pharmaceuticals was 12.60% per year. The lowest was -75.70% per year. And the median was -11.90% per year.
TARS's 3-Year EBIT Growth Rate is ranked worse than 53.38% of 1182
companies
in the Biotechnology industry
Industry Median: 15.45
vs TARS: 12.60
Tarsus Pharmaceuticals (NAS:TARS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Tarsus Pharmaceuticals EBIT per Share Related Terms
Tarsus Pharmaceuticals EBIT per Share Historical Data
* Premium members only.
The historical data trend for Tarsus Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a EBIT per Share of $-0.84 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tarsus Pharmaceuticals and its competitors. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #631 out of 1182 companies in the Biotechnology industry, placing it in the top 53.4%.
Is Tarsus Pharmaceuticals' EBIT per Share too high?
Tarsus Pharmaceuticals' current EBIT per Share is $-0.84. Based on the distribution chart, Tarsus Pharmaceuticals ranks #631 out of 1182 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tarsus Pharmaceuticals has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' EBIT per Share compare to VERA and IDYA?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #631 out of 1182 companies for EBIT per Share. This places Tarsus Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,182 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current EBIT per Share is $-0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $202.09, compared to a current price of $62.92 — trading 68.9% below its estimated fair value. The current EBIT per Share is $-0.84. Tarsus Pharmaceuticals' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current EBIT per Share is $-0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $62.92 is trading 68.9% below its estimated GF Value™ of $202.09.
GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TARS:
EBIT per Share: $-0.84
GF Value™: $202.09 vs. price of $62.92 (68.9% below fair value)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
48GF Score
Get the complete analysis for TARS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
